Abstract
As an adjuvant drug, alprostadil lipid microsphere injection (Lipo-PGE(1)) is one of the best-selling drugs in China in recent years. However, the off-label use of Lipo-PGE(1) is very common. This study aimed to investigate the use of Lipo-PGE(1) and evaluate the clinical effects and economic benefits after administrative intervention on inappropriate use of Lipo-PGE(1) in neurosurgical patients in a Chinese tertiary hospital. Administrative interventions were implemented from January to December 2018 by reducing the procurement volume of Lipo-PGE(1), judging the rationality of medical records, and establishing reward and punishment mechanisms. Administrative interventions significantly decreased prescription rate (49.98% vs 22.49%), utilization (22,311 DDDs vs 8334 DDDs), drug use density (43.52 DDDs/TID vs 15.84 DDDs/TID), total expenditure (3.58 million RMB vs 1.30 million RMB), and average expenditure (2025.04 RMB vs 1466.49 RMB) of Lipo-PGE(1). To our delight, these intervention effects were maintained or even better in the 1-year post-intervention period. Moreover, in the intervention and post-intervention phases, the Lipo-PGE(1) use for no indications as well as inappropriate drug dose, frequency, menstruum type, combination, and contraindication were markedly reduced. Besides, the mean costs (P < 0.001), and mean duration (P < 0.001) of Lipo-PGE(1) were also obviously decreased. The administrative intervention obviously reduced the off-label use of Lipo-PGE(1). However, there still remains a number of inappropriate uses of Lipo-PGE(1). To further improve the rational use of Lipo-PGE(1), combination of administrative intervention and real-time clinical pharmacists intervention should be implemented.